EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis

Sevan N Alwan iD, Alexander B Taylor, Jayce Rhodes, Michael Tidwell, Stanton F McHardy, Philip T LoVerde

PLOS Pathogens · 10.07.2023 · 19 (7) · e1011018

DOI: 10.1371/journal.ppat.1011018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 10.07.2023. Verfasst von Sevan N Alwan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Biochemistry and Structural Biology, University of Texas Health at San Antonio; San Antonio, Texas, Unites States of America. Hauptthemen laut MEDLINE: Schistosomiasis, Schistosomiasis mansoni, Anthelmintics. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human schistosomiasis is a neglected tropical disease caused by Schistosoma mansoni , S . haematobium , and S . japonicum . Praziquantel (PZQ) is the method of choice for treatment. Due to constant selection pressure, there is an urgent need for new therapies for schistosomiasis. Previous treatment of S . mansoni included the use of oxamniquine (OXA), a drug that is activated by a schistosome sulfotransferase (SULT). Guided by data from X-ray crystallography and Schistosoma killing assays more than 350 OXA derivatives were designed, synthesized, and tested. We were able to identify CIDD-0150 610 and CIDD-0150 303 as potent derivatives in vitro that kill (100%) of all three Schistosoma species at a final concentration of 71.5 μM. We evaluated the efficacy of the best OXA derivates in an in vivo model after treatment with a single dose of 100 mg/kg by oral gavage. The highest rate of worm burden reduction was achieved by CIDD -150 303 (81.8%) against S . mansoni , CIDD-0149 830 (80.2%) against S . haematobium and CIDD-066 790 (86.7%) against S . japonicum . We have also evaluated the ability of the derivatives to kill immature stages since PZQ does not kill immature schistosomes. CIDD-0150 303 demonstrated (100%) killing for all life stages at a final concentration of 143 μM in vitro and effective reduction in worm burden in vivo against S . mansoni . To understand how OXA derivatives fit in the SULT binding pocket, X-ray crystal structures of CIDD-0150 303 and CIDD-0150 610 demonstrate that the SULT active site will accommodate further modifications to our most active compounds as we fine tune them to increase favorable pharmacokinetic properties. Treatment with a single dose of 100 mg/kg by oral gavage with co-dose of PZQ + CIDD-0150303 reduced the worm burden of PZQ resistant parasites in an animal model by 90.8%. Therefore, we conclude that CIDD-0150 303 , CIDD-0149 830 and CIDD-066 790 are novel drugs that overcome some of PZQ limitations, and CIDD-0150 303 can be used with PZQ in combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchistosomiasisSchistosomiasis mansoniAnthelminticsAnimalsHumansPraziquantelOxamniquineSchistosoma mansoniCombined Modality TherapyNeglected Diseases

Substanzen

PraziquantelOxamniquineAnthelmintics

Autor:innen und Institutionen

  • Departments of Biochemistry and Structural Biology, University of Texas Health at San Antonio; San Antonio, Texas, Unites States of America.
  • Biology Core Facilities, University of Texas Health at San Antonio; San Antonio, Texas, Unites States of America.
  • Center for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio; San Antonio, Texas, Unites States of America.

ORCID-Profile: Sevan N Alwan

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Allergy and Infectious Diseases
  • Morrison Trust
  • National Institutes of Health

Zitieren

APA

Alwan, S. N., Taylor, A. B., Rhodes, J., Tidwell, M., McHardy, S. F., & LoVerde, P. T. (2023). Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. PLOS Pathogens, 19(7), e1011018. https://doi.org/10.1371/journal.ppat.1011018

Vancouver

Alwan SN, Taylor AB, Rhodes J, Tidwell M, McHardy SF, LoVerde PT. Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. PLOS Pathogens. 2023;19(7):e1011018. doi:10.1371/journal.ppat.1011018

BibTeX
@article{Alwan2023,
  author = {Alwan, Sevan N and Taylor, Alexander B and Rhodes, Jayce and Tidwell, Michael and McHardy, Stanton F and LoVerde, Philip T},
  title = {Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis},
  journal = {PLOS Pathogens},
  year = {2023},
  volume = {19},
  number = {7},
  pages = {e1011018},
  doi = {10.1371/journal.ppat.1011018}
}
Kostenlos starten →